1. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. (11th June 2018) Authors: Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J -Y Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1777 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA13Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. (23rd October 2018) Authors: Gluz, O; Nitz, U; Liedtke, C; Christgen, M; Grischke, E-M; Forstbauer, H; Braun, M; Warm, M; Hackmann, J; Uleer, C; Aktas, B; Schumacher, C; Lindner, C; Kümmel, S; Kates, R E; Potenberg, J; Staib, P; Wuerstlein, R; Kreipe, H H; Harbeck, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗